cardionogen-2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	662931
CHEMBL ID	1519124
MeSH ID	M0572925

Synonyms (22)

Synonym
AO-365/43401691
6-(3,4-dimethoxyphenyl)-3-(2-pyridinyl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole
smr000043689
MLS000081176 ,
NCGC00019285-01
VU0247828-3
STK824511
6-(3,4-dimethoxyphenyl)-3-(pyridin-2-yl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole
6-(3,4-dimethoxyphenyl)-3-pyridin-2-yl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole
AKOS005612541
NCGC00019285-02
HMS2396L23
6-(3,4-dimethoxyphenyl)-3-(2-pyridyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole
bdbm38325
cid_662931
6-(3,4-dimethoxyphenyl)-3-(2-pyridinyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole
CHEMBL1519124
cardionogen-2, >=98% (hplc)
578755-52-9
cardionogen 2
cardionogen-2
PD128108

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (14)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	44.6684	0.0447	17.8581	100.0000	AID485294
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	19.9526	0.6310	35.7641	100.0000	AID504339
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	28.1838	0.1778	14.3909	39.8107	AID2147
glp-1 receptor, partial	Homo sapiens (human)	Potency	11.2947	0.0184	6.8060	14.1254	AID624172; AID624417
ClpP	Bacillus subtilis	Potency	22.3872	1.9953	22.6730	39.8107	AID651965
ATAD5 protein, partial	Homo sapiens (human)	Potency	32.6427	0.0041	10.8903	31.5287	AID504467
TDP1 protein	Homo sapiens (human)	Potency	32.6427	0.0008	11.3822	44.6684	AID686979
PINK1	Homo sapiens (human)	Potency	28.1838	2.8184	18.8959	44.6684	AID624263
Parkin	Homo sapiens (human)	Potency	28.1838	0.8199	14.8306	44.6684	AID624263
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	44.6684	0.7079	36.9043	89.1251	AID504333
muscleblind-like protein 1 isoform 1	Homo sapiens (human)	Potency	22.3872	0.0041	9.9625	28.1838	AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
dCTP pyrophosphatase 1	Homo sapiens (human)	IC50 (µMol)	0.0790	0.0790	0.0790	0.0790	AID1440777
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
mitogen-activated protein kinase kinase kinase kinase 2 isoform 1	Homo sapiens (human)	EC50 (µMol)	30.0000	0.6700	8.5344	26.3600	AID2150; AID2151
mitogen-activated protein kinase kinase kinase 3 isoform 1	Homo sapiens (human)	EC50 (µMol)	30.0000	2.6800	6.6700	11.8600	AID2145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Process	via Protein(s)	Taxonomy
dTTP catabolic process	dCTP pyrophosphatase 1	Homo sapiens (human)
dCTP catabolic process	dCTP pyrophosphatase 1	Homo sapiens (human)
nucleoside triphosphate catabolic process	dCTP pyrophosphatase 1	Homo sapiens (human)
DNA protection	dCTP pyrophosphatase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Process	via Protein(s)	Taxonomy
magnesium ion binding	dCTP pyrophosphatase 1	Homo sapiens (human)
protein binding	dCTP pyrophosphatase 1	Homo sapiens (human)
pyrimidine deoxyribonucleotide binding	dCTP pyrophosphatase 1	Homo sapiens (human)
identical protein binding	dCTP pyrophosphatase 1	Homo sapiens (human)
nucleoside triphosphate diphosphatase activity	dCTP pyrophosphatase 1	Homo sapiens (human)
dCTP diphosphatase activity	dCTP pyrophosphatase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Process	via Protein(s)	Taxonomy
nucleus	dCTP pyrophosphatase 1	Homo sapiens (human)
nucleoplasm	dCTP pyrophosphatase 1	Homo sapiens (human)
mitochondrion	dCTP pyrophosphatase 1	Homo sapiens (human)
cytosol	dCTP pyrophosphatase 1	Homo sapiens (human)
cytosol	dCTP pyrophosphatase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1440810	Stability of the compound in biochemical assay buffer under basic mobile phase conditions by HPLC-MS analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440809	Stability of the compound in biochemical assay buffer under mildly acidic mobile phase conditions by HPLC-MS analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440781	Half life in human liver microsomes up to 100 uM preincubated for 10 mins followed by NADPH addition by UPLC-MS analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440787	Fraction unbound in human plasma	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440807	Inhibition of dCTPase 1 in human HL60 cells assessed as potentiation of 0.5 to 10 uM 5-AzaC-induced cytotoxicity by measuring decrease in cell viability after 72 hrs by resazurin assay	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440777	Inhibition of recombinant human N-terminal His-tagged dCTPase 1 expressed in Escherichia coli BL21(DE3)pLysS using dCTP as substrate after 1 hr by malachite green reagent based assay	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440785	Hepatic extraction ratio in mouse liver microsomes up to 100 uM preincubated for 10 mins followed by NADPH addition by UPLC-MS analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440786	Metabolic stability in human plasma after 4 hrs	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440783	Kinetic solubility of the compound	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440779	Binding affinity to recombinant human N-terminal His-tagged dCTPase 1 expressed in Escherichia coli BL21(DE3)pLysS assessed as change in melting temperature at 33 uM by Sypro Orange dye based DSF assay	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440806	Cytotoxicity against human HL60 cells assessed as decrease in cell viability at 1 to 5 uM after 72 hrs by resazurin assay	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440805	Inhibition of dCTPase 1 in human HL60 cells assessed as potentiation of 5-AzaC-induced cytotoxicity by measuring decrease in cell viability at 1 to 5 uM after 72 hrs by resazurin assay	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440780	Half life in mouse liver microsomes up to 100 uM preincubated for 10 mins followed by NADPH addition by UPLC-MS analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440778	Stability of the compound in DMSO measured after several months by HPLC-MS analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440788	Intracellular bioavailability in human HL60 cells assessed as ratio of fraction unbound in cells to intracellular drug accumulation at 0.5 uM after 45 mins by LC-MS/MS analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
AID1440784	Hepatic extraction ratio in human liver microsomes up to 100 uM preincubated for 10 mins followed by NADPH addition by UPLC-MS analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	4 (66.67)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.35 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.30 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
triptolide [no description available]	2.15	1	0	diterpenoid; epoxide; gamma-lactam; organic heteroheptacyclic compound	antispermatogenic agent; plant metabolite

Condition	Indicated	Relationship Strength	Studies	Trials
Innate Inflammatory Response [description not available]	0	2.05	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.05	1	0

chemdatabank.com